Abstract
Cytomegalovirus (CMV) antibody testing is currently limited by manufacturers' guidelines to specimens stored for 7 days or less. We examined the stability of CMV antibodies in plasma from platelets and whole-blood units during storage using a rapid, automated, recombinant protein-based immunoassay which qualitatively detects total antibody to human CMV. Testing of single-donor apheresis platelets was performed on baseline serum and platelet-free plasma and on platelet-free plasma 8 days later. Indeterminate, positive, and negative CMV antibody results were maintained over time for 97% (75 of 77) of the platelet specimens. For whole-blood units, initial testing of donor serum and plasma obtained from erythrocyte segments took place within 7 days of phlebotomy. Indeterminate, positive, and negative CMV antibody results were maintained on subsequent analyses performed on erythrocyte segments at 2, 4, 6, and 8 weeks for 100% of whole-blood specimens. An important potential benefit of CMV antibody testing of stored platelets and blood is the elimination of a costly, dedicated, CMV-negative inventory. The study suggests that CMV antibody testing can be conveniently and reliably performed on blood components over the entire storage period.
Full Text
The Full Text of this article is available as a PDF (162.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andreu G., Dewailly J., Leberre C., Quarre M. C., Bidet M. L., Tardivel R., Devers L., Lam Y., Soreau E., Boccaccio C. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. 1988 Sep;72(3):964–969. [PubMed] [Google Scholar]
- DePalma L., Criss V. R., Sullivan M. T., Leitman S. F., Williams A. E., Luban N. L. Detection of cytomegalovirus antibody in platelet concentrates by fluorescence immunoassay and latex agglutination. Transfusion. 1991 Mar-Apr;31(3):245–248. doi: 10.1046/j.1537-2995.1991.31391165174.x. [DOI] [PubMed] [Google Scholar]
- Elfenbein G. J., Siddiqui T., Rand K. H., Graham-Pole J., Marcus R. B., Mendenhall N. P., Goedert T. M., Wikle-Fisher T., Gross S. A., Weiner R. S. Successful strategy for prevention of cytomegalovirus interstitial pneumonia after human leukocyte antigen-identical bone marrow transplantation. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S805–S810. doi: 10.1093/clinids/12.supplement_7.s805. [DOI] [PubMed] [Google Scholar]
- Goodnough L. T., Riddell J., 4th, Lazarus H., Chafel T. L., Prince G., Hendrix D., Yomtovian R. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang. 1993;65(2):103–107. doi: 10.1111/j.1423-0410.1993.tb02124.x. [DOI] [PubMed] [Google Scholar]
- Hillyer C. D., Snydman D. R., Berkman E. M. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products. Transfusion. 1990 Sep;30(7):659–666. doi: 10.1046/j.1537-2995.1990.30790385528.x. [DOI] [PubMed] [Google Scholar]
- Keenan R. J., Lega M. E., Dummer J. S., Paradis I. L., Dauber J. H., Rabinowich H., Yousem S. A., Hardesty R. L., Griffith B. P., Duquesnoy R. J. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991 Feb;51(2):433–438. doi: 10.1097/00007890-199102000-00032. [DOI] [PubMed] [Google Scholar]
- Klinedinst A. F., Baldwin M. L., Ness P. M. Detection of cytomegalovirus antibody in stored blood products using latex agglutination. Transfusion. 1988 Nov-Dec;28(6):563–565. doi: 10.1046/j.1537-2995.1988.28689059032.x. [DOI] [PubMed] [Google Scholar]
- Käriäinen L., Klemola E., Paloheimo J. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br Med J. 1966 May 21;1(5498):1270–1272. doi: 10.1136/bmj.1.5498.1270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mangano M. M., Chambers L. A., Kruskall M. S. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol. 1991 May;95(5):733–738. doi: 10.1093/ajcp/95.5.733. [DOI] [PubMed] [Google Scholar]
- Miller W. J., McCullough J., Balfour H. H., Jr, Haake R. J., Ramsay N. K., Goldman A., Bowman R., Kersey J. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 1991 Mar;7(3):227–234. [PubMed] [Google Scholar]
- Nankervis G. A., Kumar M. L. Diseases produced by cytomegaloviruses. Med Clin North Am. 1978 Sep;62(5):1021–1035. doi: 10.1016/s0025-7125(16)31752-7. [DOI] [PubMed] [Google Scholar]
- Smyth R. L., Scott J. P., Borysiewicz L. K., Sharples L. D., Stewart S., Wreghitt T. G., Gray J. J., Higenbottam T. W., Wallwork J. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis. 1991 Dec;164(6):1045–1050. doi: 10.1093/infdis/164.6.1045. [DOI] [PubMed] [Google Scholar]
- Sniecinski I., O'Donnell M. R., Nowicki B., Hill L. R. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988 May;71(5):1402–1407. [PubMed] [Google Scholar]
- Wenz B., Burns E. R. Phenotypic characterization of white cells in white cell-reduced red cell concentrate using flow cytometry. Transfusion. 1991 Nov-Dec;31(9):829–834. doi: 10.1046/j.1537-2995.1991.31992094671.x. [DOI] [PubMed] [Google Scholar]
- Winston D. J., Ho W. G., Champlin R. E. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S776–S792. doi: 10.1093/clinids/12.supplement_7.s776. [DOI] [PubMed] [Google Scholar]